The Development of 3D Liver Organoids for Transfection-Based Disease Modeling

The development of 3D liver organoids marks a significant advance in modeling liver physiology and pathology in vitro. Derived from pluripotent stem cells, adult stem/progenitor cells, or primary tissue, liver organoids consist of hepatocytes and often cholangiocytes in a spherical or tissue-like arrangement that allows cell polarity, multi-lineage interactions, and liver-specific functions (e.g., albumin secretion, cytochrome P450 activity) to emerge. These organoids provide a bridge between simplistic monolayer cultures and complex in vivo liver, enabling more accurate disease modeling and drug testing.

Transfection-based techniques are vital for interrogating organoid biology – whether by introducing disease-causing mutations via CRISPR, delivering reporters to track organoid development, or testing gene therapy constructs for efficacy. However, delivering genes to 3D organoids is inherently more difficult than to 2D cells. Organoids are typically grown embedded in extracellular matrix (like Matrigel) and have multiple cell layers, limiting the access of transfection reagents or viral vectors. This review highlights methods to overcome these barriers and the successes achieved in genetically modifying liver organoids for disease modeling.

Creating Liver Organoids and Transfecting Them

Liver organoids can be created from human or animal cells, often using a cocktail of growth factors (like WNT, R-spondin, EGF, etc.) to support either hepatocyte- or cholangiocyte-rich organoid outgrowth. Once established, organoids are maintained in a 3D matrix that resembles basement membrane. For transfection:

• Transient transfection of organoids: Traditional lipofection in organoids is possible but less efficient. The dense ECM (as discussed in the ECM section) and tight junctions in organoids present a barrier. Some commercial reagents have been tailored for 3D transfection; for instance, 3D-FectIN™ is a polymeric reagent reported to transfect cells within hydrogels with high efficiency. It can carry DNA through the matrix to cells in the interior of spheroids or organoids. Researchers using such reagents have managed to express fluorescent proteins in a significant fraction of organoid cells, though optimization is often needed for each organoid system.
• Electroporation and Nucleofection: These physical methods can introduce plasmids or RNP complexes into organoid cells, especially during the organoid dissociation and reformation process. A protocol often used is to dissociate organoids into a single-cell suspension or small clusters, mix them with plasmid DNA or CRISPR ribonucleoproteins, and then electroporate (for example, using a Nucleofector device). Afterward, the cells are re-plated in Matrigel to re-form organoids. Studies have shown that this approach yields genetically modified organoids. For instance, gene editing of human liver organoids via CRISPR has been accomplished: researchers have transfected organoid cells with a plasmid encoding Cas9 and a guide RNA targeting a gene like KRT19 (keratin 19) to create knockout organoids. Using a donor template plasmid, they even achieved precise knock-ins in organoids. One group demonstrated efficient HDR (homology-directed repair) in ductal organoids by co-transfecting a Cas9 plasmid, an sgRNA plasmid, and a repair template plasmid – showing that multi-component transfection can work in organoids.
• Viral transduction: Though not a “transfection” per se, viruses are commonly used to deliver genes to organoids. Lentiviruses and AAVs can infect organoids, especially if microinjecting the virus into the organoid or transducing organoids when they are small. A recent study developed an AAV variant (AAV-DJ) to transduce mouse and human liver ductal organoids efficiently They showed high transgene expression, enabling gene addition studies in organoids. Yet, viral methods have limitations like cargo size and potential integration (for lentivirus). Non-viral transfection remains valuable for simpler, potentially cleaner modifications.

Altogen’s realm is largely non-viral transfection reagents. While they might not have a dedicated organoid transfection kit publicly, their general reagents could be tried for organoids. If an organoid is derived from, say, HepG2 cells or primary hepatocytes, Altogen’s HepG2 reagent or in vivo reagent might be attempted. There’s also Altogen’s mention of a PEG-Liposome in vivo kit and other advanced formulations which could theoretically be applied to organoids to improve penetration.

Disease Modeling with Transfected Organoids

The goal of transfecting or editing liver organoids is often to create a disease model. Examples include:

• Genetic liver diseases: Researchers have used CRISPR to introduce specific mutations into healthy organoids to simulate diseases. For example, introducing a mutation in the alpha-1 antitrypsin (A1AT, SERPINA1 gene) gene in organoids to model A1AT deficiency, which leads to mutant protein accumulation in hepatocytes and eventually liver damage. By transfecting a guide targeting SERPINA1, they produced organoids with the Z allele mutation and studied disease phenotypes in vitro.
• Oncology: Liver cancer organoids derived from patient tumors can be expanded. To study gene function or test therapies, scientists co-transfect these cancer organoids with a therapeutic gene or a reporter. For instance, one could introduce a suicide gene (like HSV-TK) into liver cancer organoids and then apply prodrug to test gene therapy effect in a 3D context. Co-transfection of a GFP might highlight which organoid cells took up the gene.
• Drug metabolism and toxicity: Organoids express many liver functions, so they can be used to examine drug-induced liver injury. Transfecting organoids with reporters (like a sensor for oxidative stress or an apoptotic indicator) can allow real-time monitoring of cellular responses to drugs. A high-throughput approach might involve transfecting organoids in 96-well plates with a fluorescent reporter and then dosing drugs to see if certain conditions (like a gene knockout vs. wild-type organoid) lead to higher toxicity.

One study created engineered human hepatocyte organoids where they used CRISPR activation (CRISPRa) to upregulate certain genes within organoids to see how it affects hepatitis virus replication. They transfected organoids with a dCas9-activator plasmid and guide RNAs to temporarily boost expression of entry receptors for viruses, demonstrating the flexibility of gene modulation in organoids.

• Liver fibrosis: Co-culture organoids including stellate cells can simulate fibrosis. By transfecting or editing such organoids (e.g., knocking out TGF-β receptor in stellate cells via transfection of CRISPR components), one could create an organoid that does not develop fibrosis in response to injury signals, effectively modeling anti-fibrotic therapy at a mini-liver scale.

Altogen Labs may not have organoid-specific services listed, but given their expertise, they could assist in organoid experiments by applying their transfection reagents to organoids and then performing downstream analysis. For example, they could perform qPCR or ELISA on organoid culture supernatants to measure how a transfected gene alters function (they mention offering gene expression analysis services which could be relevant).

Relevance and Future Directions

3D liver organoids transfected with disease alleles or therapeutic constructs are a cutting-edge platform for testing gene therapies in a patient-specific manner. For instance, one could take a patient’s cells, grow organoids with the patient’s genetics, then transfect a CRISPR base editor aimed at correcting a mutation to see if it rescues the phenotype in the organoid. Such ex vivo trials can inform actual therapy in the patient.

Co-transfection remains relevant here: an example is co-transfecting an organoid with a GFP reporter and a therapeutic gene to identify successfully modified cells for analysis. Or co-delivering multiple components like Cas9 and multiple sgRNAs to knock out a gene family in an organoid simultaneously (which has been done in some contexts).

Conclusion

The rise of 3D liver organoids is transforming how we model liver diseases and test interventions, and transfection-based genetic manipulation is a key enabling technology in this field. Despite the inherent challenges of delivering genes into a complex 3D structure encased in extracellular matrix, researchers have developed innovative solutions – from using 3D-optimized transfection reagents, to temporarily dissociating organoids for electroporation, to refining viral vectors for organoid infection. These efforts have borne fruit: liver organoids have been successfully gene-edited to emulate disease mutations, and conversely, gene-corrected to reverse disease phenotypes, demonstrating potential for personalized regenerative medicine.

By utilizing organoids, scientists can observe how a genetic change (introduced via transfection or CRISPR) manifests in a tissue-like context – for example, how a mutation affects not just isolated hepatocytes but also their interaction with cholangiocytes or stromal elements in the organoid. This is providing insights that 2D culture could not. Altogen Biosystems’ and Altogen Labs’ expertise in transfection can contribute to this domain by supplying reagents that maintain efficiency even in the presence of extracellular matrices, and by offering analytical assays to evaluate transfection outcomes (e.g., viability assays or fluorescent imaging in 3D).

In conclusion, the development of 3D liver organoids for transfection-based disease modeling represents a convergence of tissue engineering and genetic engineering. As transfection methods continue to improve – potentially incorporating physical aids like microinjection or advanced nanocarriers that can diffuse through organoid matrices – we will be able to create ever more accurate liver models. These models will be instrumental in studying genetic liver diseases, testing gene therapies and drugs, and perhaps even producing transplantable corrected tissues in the future. The collaboration between organoid technology and transfection tools exemplifies the interdisciplinary innovation driving modern preclinical research.

Sources: Achievements in transducing/transfecting liver organoids; CRISPR editing examples in organoids; 3D transfection reagents usage